Legal Psychedelics in the US: State by State Status and Pathways
A definitive, plain-English guide to the legal landscape of psychedelics in the United States, with a focus on federal law, state-level exceptions, and the future of therapeutic access.
Are Psychedelics Legal in the United States?
No, psychedelics such as psilocybin are not legal for general use in the United States. Under federal law, classic psychedelics—including psilocybin (the active compound in "magic mushrooms"), LSD (lysergic acid diethylamide), DMT (dimethyltryptamine), and mescaline—are classified as Schedule I substances under the Controlled Substances Act (CSA). This means they are considered to have a high potential for abuse, no currently accepted medical use, and a lack of accepted safety for use under medical supervision. As of this writing, no psychedelic substance has received full approval from the US Food and Drug Administration (FDA) for any indication.
However, a small but growing number of states have enacted exceptions for specific psychedelic substances, most notably psilocybin, for supervised therapeutic use. This is a rapidly evolving area of law. This article provides general information only and does not constitute legal advice.
Federal Law: The Baseline for Psychedelics
The federal government, through the Drug Enforcement Administration (DEA) and the Controlled Substances Act, sets the baseline for drug legality in the US. As of now:
- Psilocybin is Schedule I (21 U.S.C. § 812(c)), making its possession, manufacture, or distribution illegal except for federally approved research.
- LSD, DMT, and mescaline are also Schedule I.
- MDMA ("ecstasy") is Schedule I, though it is in late-stage clinical trials for PTSD.
- Ketamine is Schedule III and FDA-approved for anesthesia and, as esketamine, for depression—but is not considered a classic psychedelic.
There are no FDA-approved psychedelic medicines as of this writing. Compass Pathways' COMP360 psilocybin therapy and Usona Institute's IPR001 are in Phase 3 trials, with FDA submissions underway, but approval and rescheduling have not yet occurred. For a full research landscape, see our psychedelic research landscape guide.
State-by-State Exceptions: Oregon and Colorado Lead
While federal law is supreme, states can create their own exceptions, especially around medical or supervised adult use. As of now, only two states have established legal frameworks for psilocybin therapy:
Oregon: Measure 109
Oregon was the first state to legalize supervised psilocybin services for adults 21 and over, via Measure 109 (2020). The program launched in 2023. Key features:
- Psilocybin can only be consumed at licensed service centers under the supervision of trained facilitators.
- No prescription or diagnosis is required, but use is restricted to controlled settings; personal possession outside these centers remains illegal.
- Oregon's program is regulated by the Oregon Health Authority (OHA).
For more on Oregon's legal framework, see our psychedelic law guide.
Colorado: Proposition 122
Colorado voters passed Proposition 122 in 2022, launching a regulated adult-use psilocybin program in 2024-2025. The law:
- Allows adults 21+ to access psilocybin at licensed healing centers under supervision.
- Decriminalizes personal use, possession, and sharing of certain natural psychedelics (psilocybin, psilocin, DMT, ibogaine, mescaline—not derived from peyote).
- Does not allow commercial retail sales outside regulated centers.
Other states have considered or enacted limited decriminalization (e.g., personal use in some cities), but no other state currently allows legal, regulated access to psychedelics for therapy or adult use.
Decriminalization vs. Legalization: What’s the Difference?
It is important to distinguish between decriminalization and legalization:
- Decriminalization means reducing or eliminating criminal penalties for possession or use, but not creating a legal supply chain or regulated access. Examples include city-level policies in Denver, Oakland, and Seattle.
- Legalization means creating a legal, regulated system for production, distribution, and supervised use. Only Oregon and Colorado have done this for psilocybin.
In most US jurisdictions, psychedelics remain illegal and subject to criminal penalties. For more on the legal landscape, see our psychedelic law and briefing sections.
Therapeutic Access: FDA Pathways and Clinical Trials
While state programs are pioneering regulated access, the main pathway to widespread legal psychedelic therapy remains through FDA approval and subsequent rescheduling. As of now:
- Psilocybin is in Phase 3 trials for depression (Compass Pathways' COMP360 and Usona Institute's IPR001).
- Compass Pathways has submitted a New Drug Application (NDA) to the FDA, a first for a classic psychedelic.
- If approved, the DEA would likely reschedule psilocybin for medical use, enabling prescription in regulated clinical settings nationwide.
- MDMA-assisted therapy for PTSD is also in late-stage review, and could become the first FDA-approved psychedelic-assisted therapy.
For a deeper dive into research, see our research landscape and briefing feeds.
What Should Researchers, Investors, and Patients Do Next?
The US legal landscape for psychedelics is in flux. Key points for stakeholders:
- Researchers should ensure compliance with federal law and seek DEA and FDA approvals for any work with Schedule I substances.
- Investors should monitor FDA review timelines, state program implementation, and evolving insurance and reimbursement policies.
- Patients outside Oregon and Colorado do not have legal access to psilocybin therapy, except through clinical trials or expanded access programs.
- For the latest updates and practical tools, visit our guides and tools sections.
Always consult a qualified attorney before making decisions based on state or federal drug laws.